Search
Patient organizations
EHA greatly values the collaboration with patient organizations in a growing number of areas, from joint advocacy and a strong presence at the EHA Annual Congress – with a prominent place for the EHA-Patient Joint Symposium on policy and regulatory…
Read moreRecap: European Affairs and Hematology at EHA2024
As at previous congresses, the European Affairs track at EHA2024 offered opportunities to learn, exchange, and connect.
Read moreDeadlines & Announcements
New announcements will be published as soon as new elements for the Congress Sponsor Program for EHA2025 are released.
Read moreCongress Sponsor Program
Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.
Read moreHighlights from the SWG
Impactful activitiesGuideline development projectThe most relevant and impactful activities of the SWG include those related to the guideline development project. There were regular meetings with the Guidelines Expert Panel Committee.
Read moreSWG Educational Activities
Past EHA (HOPE) Asia 2021 meeting 10-11 September 2021, Virutal
Speakers
Laane - Systematic review of literature on multiple myeloma EHA evidence-based “Guidelines for the use of patient-reported outcomes in adult patients with hematological malignancies” in progress - Systematic review of literature…
Publications
The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review
Salek, S. ; Ionova, T. ; Oliva, E. N. ; Andreas, M. ; Skoetz, N. ; Kreuzberger, N. ; Laane, E.
Highlights from the SWG
SWG Session at EHA2023ELN-EHA SWG for CML: CML: modelling the futureChairJane Apperley (United Kingdom)
Topics and presenters
Identifying new targets for BCR::ABL1 inhibition: Oliver Hantschel (Germany). Dissecting phylogenetic trees in CML: Aleksandra Kamizela (United Kingdom).
Publications
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.